Intro
National Institute of Parasitic Diseases, China: 70 Years and Beyond
Copyright
Contents
Contributors
Preface: Development strategy of NIPD-CTDR in the new era
1. Foreword
2. Major achievements
2.1. Promoting parasitic diseases from control to elimination
2.2. Promoting technological innovation in national medical parasitology
2.3. Promoting the disciplinary development in tropical medicine and global health
3. Future orientations
References
Chapter One: Contributions and achievements on schistosomiasis control and elimination in China by NIPD-CTDR
1. Introduction
2. The endemic status of schistosomiasis in P.R. China
3. Transmission patterns and evolution of the control strategy on schistosomiasis
3.1. Epidemiological patterns
3.1.1. Plains & water network regions
3.1.2. Marshlands & lakes regions
3.1.2.1. Combination of sluice construction and snail control in the Poyang Lake
3.1.2.2. Test for snail control by aircraft spraying
3.1.3. Hilly & mountainous regions
3.1.4. The influence of Three Gorges Dam on schistosomiasis transmission
3.2. Strategy evolution
3.2.1. The first stage, from the mid-1950s to the early 1980s
3.2.2. The second stage, from the 1980s to the beginning of the 21st century
3.2.3. The third stage, from 2004 to present
4. Diagnostics and vaccine development
4.1. Development and application of diagnostics
4.1.1. Parasitological diagnosis
4.1.1.1. Hatching test
4.1.1.2. Improved Kato-Katz method combined with faecal hatching evaluation
4.1.2. Immunological diagnosis
4.1.2.1. The intradermal test
4.1.2.2. Cercarien-Hullen-Reaktion
4.1.2.3. The circumoval precipitin test
4.1.2.4. Latex agglutination test
4.1.2.5. Enzyme-linked immunoelectron transfer blot assay
4.1.2.6. Enzyme-linked immunosorbent assay
4.1.2.7. Rapid diagnostic kits
4.1.3. Assessment of diagnostic assays and quality control
4.1.3.1. Assessment of diagnostic assays
4.1.3.2. Quality control
4.2. Vaccines development
4.2.1. Vaccine candidate antigens
4.2.2. Multivalent vaccines
4.2.3. Immunization test on cattle
5. Research and development of drugs and molluscicides
5.1. Drug development for human treatment
5.1.1. Praziquantel
5.1.1.1. Effect of praziquantel on the nervous system activity of schistosomes
5.1.1.2. Effect of praziquantel on the metabolism of schistosomes
5.1.1.3. Effect of praziquantel on the ultrastructure of different stages of schistosomes
5.1.1.4. Comparison of the effects of different structures of praziquantel on schistosomes
5.1.2. Artemether
5.1.2.1. Mechanism of action
5.1.2.2. Field trials
5.1.3. Other new anti-schistosomiasis drugs
5.2. Molluscicides development
5.2.1. Bromoacetamide
5.2.2. Niclosamide
5.2.3. Development of novel chemical molluscicides